Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levitiracetam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levetiracetam SCHEMBL5072485 | 1.00 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL373194 | 1.00 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL118843 | 1.00 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL17372720 | 0.98 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL28457423 | 0.98 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL22031970 | 0.98 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL28026798 | 0.98 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL6073150 | 0.95 | LMNA (0.90) | LMNACA12CA1CA2CA3 | |
| SCHEMBL660679 | 0.95 | LMNA (0.90) | LMNACA12CA1CA2CA3 | |
| SCHEMBL661433 | 0.93 | LMNA (0.87) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17961 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122071422-A | Novel crystal form of (S) -2-aminobutanamide hydrochloride and preparation method and application thereof | 浙江华海药业股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260137651-A1 | MULTI-COMPARTMENT NANOEMULSION FOR INTRANASAL DRUG DELIVERY | KING ABDULAZIZ UNIVERSITY (SA) | 2026-05-21 | — | — | US | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026102415-A1 | MICROBIAL BIOMARKERS OF CANINE IDIOPATHIC EPILEPSY | MARS, INCORPORATED (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099901-A1 | LEVETIRACETAM FOR USE IN THE TREATMENT OF PAIN CAUSED BY HYDROCEPHALUS | UNIVERSITÀ DEGLI STUDI DI FIRENZE (IT) | 2026-05-15 | — | — | WO | claimed |
| CN-122038556-A | Method for predicting sodium valproate therapeutic response based on TPH2 gene polymorphism, kit and application thereof | 深圳市宝安区妇幼保健院 | 2026-05-15 | — | — | CN | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12616680-B2 | Combined use of biotin and thiamine in the treatment of huntington's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2026-05-05 | — | — | US | claimed |
| US-6124473-A | ENANTIOMERIC RESOLUTION IS CARRIED OUT BY SIMULATED MOBILE BED CHROMATOGRAPHY, USING AT LEAST THREE COLUMNS FILLED WITH CHIRAL STATIONARY PHASE. | UCB, S.A. (BE) | 2000-09-26 | — | — | US | claimed |
| US-6107492-A | BY OPTICAL RESOLUTION OF A RACEMIC MIXTURE OF ALPHA-ETHYL-2-OXO-1-PYRROLIDINE ACETAMIDE BY CHROMATOGRAPHY USING SILICA GEL SUPPORTING AMYLOSE TRIS(3,5-DIMETHYLPHENYLCARBAMATE) AS A PACKING MATERIAL | UCB, S.A. (BE) | 2000-08-22 | — | — | US | claimed |
| WO-2000037616-A1 | COMPOUNDS, METHODS OF SCREENING AND METHODS OF TREATMENT FOR CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | CYTOSCAN SCIENCES L.L.C. (US) | 2000-06-29 | — | — | WO | claimed |
| CN-1156410-A | Anti-stress, anti-injury and anti-aging medicine and production method thereof | RIGA D (RO) | 1997-08-06 | — | — | CN | claimed |
| US-4943639-A | (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide | U C B SOCIETE ANONYME (BE) | 1990-07-24 | — | — | US | claimed |
| EP-0165919-B1 | (R)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINACETAMIDE | U C B, S.A. (BE) | 1989-08-09 | — | — | EP | claimed |
| US-4837224-A | TREATING MEMORY DISORDERS | UCB SOCIETE ANONYME (BE) | 1989-06-06 | — | — | US | claimed |
| US-4837223-A | ANTIISCHEMIC AGENTS | UCB SOCIETE ANONYME (BE) | 1989-06-06 | — | — | US | claimed |
| US-4696942-A | Treatment of memory impairment using (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide | UCB SOCIETE ANONYME (BE) | 1987-09-29 | — | — | US | claimed |
| EP-0165919-A1 | (R)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide | U C B, S.A. (BE) | 1985-12-27 | — | — | EP | claimed |